Evidence map›Paper›PMID 40968724›Full record

ArticleMolecular oncology2025

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis.

Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michela De MeoDepartment of Molecular Medicine, Sapienza University of Rome, Italy.ORCID 0000-0002-3024-2233
Marco SiringoDepartment of Molecular Medicine, Sapienza University of Rome, Italy.ORCID 0000-0002-0489-1790
Alessandro ViciDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Ann ZeunerDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Orietta GandiniDepartment of Molecular Medicine, Sapienza University of Rome, Italy.
Paola GazzanigaCancer Liquid Biopsy Unit, Department of Experimental Medicine, Sapienza University of Rome, Italy.
Chiara NicolazzoCancer Liquid Biopsy Unit, Department of Experimental Medicine, Sapienza University of Rome, Italy.

Funding

Association for Cancer Research, AIRC IG 29148European Union - Next Generation EU, PNRR-MAD-2022 12376183European Union - Next Generation EU, PNRR-RT_SPOKE_1-ROME TECHNOPOLE B83C22002820006-ECS00000024HEAL ITALIA European Union-Next Generation EU Project M4C2I1.3 under Italian Ministry of University and Research
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with metastatic CRC (mCRC) posing significant challenges due to tumor heterogeneity and resistance to therapy. Circulating tumor cells (CTC) and circulating hybrid cells (CHC) detected via liquid biopsies have emerged as promising biomarkers for monitoring disease progression. This study aimed to evaluate the prognostic utility of automated CTC enumeration using the ACCEPT software compared to a manual method and assess the potential clinical relevance of CHC in mCRC. A retrospective analysis of CellSearch

Indexed as

Colorectal NeoplasmsNeoplastic Cells, CirculatingAdultAgedAged, 80 and overAutomationCell CountFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisRetrospective StudiesACCEPTCellSearch®circulating hybrid cells (CHC)circulating tumor cells (CTC)dual‐positive cellsmetastatic colorectal cancer (mCRC)

Identifiers

PMID40968724
PMCPMC12688169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.